International Journal of ADVANCED RESEARCH & INNOVATIONS

Volume 13, Issue-12
December, 2023, P09
ISSN: 2319-9253

HUMAN–ARTIFICIAL INTELLIGENCE COLLABORATION IN ONCOLOGY: BUILDING TRUSTWORTHY CLINICAL INTELLIGENCE SYSTEMS

#1**Dr. Sandeep Chatterjee,** Associate Professor, Department of Internal Medicine, SreeMookambika Institute of Medical Sciences, Kulasekharam, India
Sandeepchatterjee63@gmail.com

Abstract: Human–artificial intelligence (AI) collaboration is redefining precision oncology by establishing trustworthy clinical intelligence systems that combine computational power with clinician expertise to improve cancer diagnosis, therapeutic decision-making, disease monitoring, and personalized patient care. Rather than replacing healthcare professionals, modern AI systems function as collaborative partners that augment multidisciplinary oncology teams through integration of radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, electronic health records, biomedical literature, and longitudinal clinical outcomes. Recent advances in foundation AI models, multimodal transformer architectures, graph neural networks, self-supervised learning, reinforcement learning, and generative artificial intelligence have enabled comprehensive multimodal reasoning across heterogeneous biomedical data while supporting explainable, adaptive, and continuously learning clinical decision support. Emerging technologies including multimodal large language models, federated learning, retrieval-augmented generation, agentic AI, digital twins, cloud-native healthcare platforms, and digital health ecosystems further strengthen collaborative intelligence by enabling transparent, privacy-preserving, evidence-based, and human-centered oncology practice. Despite remarkable technological progress, successful implementation requires overcoming challenges related to explainability, clinical validation, interoperability, algorithmic bias, cybersecurity, regulatory governance, clinician trust, patient acceptance, and ethical deployment. This review provides a comprehensive overview of human–AI collaboration in oncology, emphasizing the development of trustworthy clinical intelligence systems capable of supporting adaptive precision medicine and personalized therapeutics.[1]

Keywords: *Human–AI collaboration, Trustworthy artificial intelligence, Precision oncology, Foundation models, Clinical intelligence, Explainable AI, Clinical decision support, Digital health, Computational oncology, Personalized medicine.*

1. Introduction

Cancer management has become increasingly complex owing to the rapid expansion of molecular diagnostics, advanced medical imaging, digital pathology, precision therapeutics, immunotherapy, digital health technologies, and continuously evolving biomedical knowledge. Multidisciplinary oncology teams must integrate enormous volumes of heterogeneous biomedical information to provide accurate diagnosis, individualized treatment planning, toxicity management, survivorship care, and evidence-based clinical decision-making. Human cognitive limitations, increasing clinical workload, and expanding scientific literature have created a growing need for intelligent computational systems capable of augmenting clinical expertise rather than replacing it.[2]

Artificial intelligence has emerged as a transformative technology capable of integrating radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, electronic health records, biomedical literature, and patient-reported outcomes into unified computational representations of cancer biology. However, successful clinical implementation depends not only upon predictive accuracy but also upon transparency, interpretability, reliability, accountability, and clinician confidence.[3]

Human–AI collaboration therefore represents a new paradigm in precision oncology, where intelligent computational systems complement clinical reasoning, multidisciplinary expertise, and patient-centered decision-making to improve healthcare quality while maintaining meaningful human oversight.

2. Evolution of Human–AI Collaboration in Oncology

Artificial intelligence in oncology has evolved from isolated computer-aided diagnostic systems toward collaborative intelligence ecosystems supporting multidisciplinary clinical practice. Early AI applications primarily focused on narrow prediction tasks such as lesion classification, pathology interpretation, or survival prediction using conventional machine learning algorithms. Although these systems demonstrated promising performance, limited transparency and restricted generalizability constrained widespread clinical adoption.[4]

Deep learning substantially expanded computational capabilities through automated feature learning from radiological imaging, digital pathology, genomics, and electronic health records. Transformer architectures subsequently revolutionized biomedical AI by enabling contextual reasoning across multiple biomedical modalities.

Foundation AI models now acquire transferable biomedical knowledge through large-scale self-supervised pretraining, supporting collaborative diagnosis, biomarker discovery, therapeutic optimization, digital twin simulation, adaptive disease monitoring, and intelligent clinical decision support across diverse oncology applications.[5]

3. Principles of Trustworthy Clinical Intelligence Systems

Trustworthy clinical intelligence systems differ fundamentally from conventional predictive algorithms because they are designed to support collaborative decision-making while maintaining transparency, interpretability, accountability, robustness, fairness, and clinician oversight. Rather than generating isolated predictions, foundation AI models develop generalized biomedical representations that integrate heterogeneous information while enabling meaningful interaction with healthcare professionals.[6]

Self-supervised learning enables discovery of latent biological relationships without requiring extensive manual annotation, while multimodal transformer architectures align radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, biomedical literature, and longitudinal clinical trajectories within unified computational embedding spaces.

Graph neural networks further characterize interactions among genes, proteins, signaling pathways, immune populations, imaging phenotypes, tissue architecture, therapeutic targets, physiological variables, environmental exposures, and clinical outcomes, enabling systems-level computational reasoning while supporting transparent collaboration between clinicians and intelligent algorithms.[7]

4. Computational Architecture for Collaborative Intelligence

Modern human–AI collaborative oncology platforms consist of interconnected computational layers responsible for biomedical data acquisition, preprocessing, multimodal representation learning, explainable inference, adaptive reasoning, digital twin simulation, knowledge integration, and intelligent clinical decision support.[8]

The acquisition layer continuously integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, biomedical literature, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, synchronize temporal patient information, and continuously incorporate evolving scientific evidence.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological function, environmental exposures, and longitudinal clinical trajectories while simultaneously producing interpretable explanations supporting clinician understanding and collaborative reasoning.[9]

5. Artificial Intelligence for Collaborative Cancer Diagnosis

Collaborative diagnosis represents one of the most important applications of trustworthy AI in oncology. Foundation AI models automatically analyze radiological imaging, digital pathology, molecular biomarkers, laboratory investigations, and clinical documentation while providing clinicians with interpretable evidence supporting diagnostic reasoning.[10]

Radiologists benefit from automated lesion detection, tumor segmentation, radiomic characterization, and longitudinal imaging comparison, while pathologists receive computational assistance for histological classification, tumor grading, mitotic quantification, immune microenvironment assessment, and molecular phenotype prediction. Natural language processing further synthesizes physician documentation, pathology reports, imaging narratives, and biomedical literature into comprehensive diagnostic summaries.

Human oversight remains central throughout diagnostic workflows, allowing clinicians to validate AI recommendations, resolve ambiguous findings, incorporate contextual clinical information, and make final diagnostic decisions. This collaborative paradigm improves diagnostic consistency, workflow efficiency, and patient safety.[11]

6. Shared Decision-Making for Precision Therapeutics

Precision oncology increasingly requires integration of molecular biomarkers, genomic alterations, imaging phenotypes, histopathological findings, laboratory investigations, patient preferences, treatment history, performance status, comorbidities, and evolving scientific evidence. Foundation AI models synthesize these diverse biomedical modalities into comprehensive patient-specific representations that support multidisciplinary therapeutic decision-making.[12]

Artificial intelligence identifies clinically actionable molecular alterations, predicts therapeutic responsiveness, estimates treatment-related toxicity, evaluates recurrence risk, and summarizes evidence from clinical trials and biomedical literature. These recommendations are subsequently interpreted by oncologists who integrate patient values, quality-of-life considerations, treatment accessibility, socioeconomic factors, and clinical judgment before selecting individualized therapeutic strategies.

This collaborative decision-making process strengthens evidence-based precision oncology while preserving clinician responsibility and patient autonomy.[13]

7. Explainable Artificial Intelligence and Clinical Trust

Explainability represents one of the most essential requirements for successful human–AI collaboration. Clinicians are more likely to trust computational recommendations when algorithms provide understandable reasoning rather than opaque predictions. Explainable artificial intelligence (XAI) enables visualization of computational attention, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analyses, uncertainty estimation, confidence scoring, and counterfactual explanations identifying the biological and clinical variables responsible for individual predictions.[14]

Foundation AI models increasingly generate natural-language explanations summarizing diagnostic reasoning, molecular interpretation, therapeutic evidence, uncertainty estimates, and supporting biomedical literature. Such transparent computational reasoning enables clinicians to critically evaluate algorithmic recommendations while improving accountability, reproducibility, education, and regulatory confidence.

Explainable AI therefore serves as the foundation for trustworthy clinical intelligence systems capable of supporting routine oncology practice.[15]

8. Human–AI Collaboration in Continuous Patient Monitoring

Digital health technologies including wearable biosensors, mobile health applications, remote physiological monitoring, Internet of Medical Things (IoMT) platforms, and patient-reported outcomes continuously generate longitudinal information throughout the cancer care continuum. Foundation AI models integrate these digital biomarkers with laboratory investigations, radiological imaging, digital pathology, molecular biology, and electronic health records to identify early physiological deterioration, treatment-related toxicity, disease progression, recurrence, and supportive care requirements.[16]

Rather than replacing clinicians, AI continuously prioritizes clinically significant events while physicians interpret alerts within the broader clinical context, validate recommendations, communicate with patients, and coordinate multidisciplinary interventions. This collaborative monitoring framework improves early intervention, survivorship management, treatment adherence, and personalized supportive care.

Digital health therefore extends human–AI collaboration beyond hospitals into continuous patient-centered oncology care.[17]

9. Foundation Models for Clinical Knowledge Integration

One of the greatest strengths of foundation AI models is their ability to integrate radiological imaging, digital pathology, multi-omics, laboratory biomarkers, biomedical literature, clinical guidelines, electronic health records, digital biomarkers, patient-reported outcomes, and longitudinal clinical trajectories into comprehensive patient-specific computational representations. Rather than analyzing individual biomedical modalities independently, these models synthesize heterogeneous molecular, pathological, physiological, and clinical information while generating evidence-based recommendations that support multidisciplinary tumor boards, personalized therapeutics, adaptive disease monitoring, digital twin simulation, and precision clinical decision-making. Human expertise remains central for validating computational recommendations, resolving uncertainty, communicating with patients, balancing ethical considerations, and delivering compassionate, individualized cancer care. Together, collaborative intelligence establishes the computational foundation for trustworthy, explainable, adaptive, and continuously learning precision oncology systems.[18][19][20]

10. Digital Twins and Human–AI Collaborative Decision-Making

Digital twin technology represents one of the most advanced applications of human–artificial intelligence collaboration by creating continuously evolving virtual representations of individual cancer patients that support shared clinical reasoning between computational systems and healthcare professionals. Foundation AI models integrate serial radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating disease progression, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival.[21]

Unlike conventional predictive models that generate static recommendations, collaborative digital twins continuously update their computational representations as new biomedical information becomes available while allowing clinicians to interactively evaluate alternative therapeutic strategies. Physicians can compare treatment sequences, anticipate mechanisms of therapeutic resistance, estimate toxicity profiles, optimize supportive care, and assess long-term clinical outcomes through dynamic simulation while incorporating patient preferences, quality-of-life considerations, and contextual clinical judgment.

By combining multimodal biomedical intelligence with physician expertise, digital twins transform oncology from algorithm-centered prediction toward collaborative, transparent, and continuously adaptive precision medicine.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1209

11. Intelligent Clinical Decision Support

Foundation AI models provide the computational infrastructure for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations while maintaining meaningful clinician oversight. Rather than independently interpreting radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines, these systems synthesize diverse biomedical information into unified computational representations that support multidisciplinary oncology practice.[22]

Interactive clinical dashboards generate individualized diagnostic summaries, molecular biomarker analyses, radiomic and pathomic interpretations, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, disease progression forecasts, survival predictions, and longitudinal treatment response assessments while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, nurses, genetic counselors, biomedical engineers, computer scientists, and healthcare administrators.

Importantly, clinicians remain responsible for validating algorithmic recommendations, interpreting uncertainty, communicating risks and benefits, and making final patient-centered decisions. This collaborative model strengthens clinical confidence while preserving professional accountability.

12. Continuous Learning and Adaptive Human–AI Collaboration

A defining characteristic of trustworthy clinical intelligence systems is the ability to continuously evolve as new biomedical information becomes available while simultaneously learning from clinician expertise. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, biomedical literature, evolving clinical guidelines, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy throughout the patient's clinical journey.[23]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting, while reinforcement learning incorporates clinician feedback and longitudinal treatment outcomes into ongoing model optimization. Expert corrections, multidisciplinary tumor board discussions, and validated clinical decisions further improve algorithm robustness and generalizability.

This adaptive learning paradigm establishes oncology as a continuously improving healthcare ecosystem where artificial intelligence and human expertise evolve together to support increasingly personalized and evidence-based cancer care.

13. Federated Collaborative Intelligence Networks

Development of highly generalizable and trustworthy foundation AI models requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, pathology laboratories, molecular technologies, wearable ecosystems, treatment protocols, and patient populations. Federated learning enables collaborative development of clinical intelligence systems while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local models using radiological imaging, digital pathology, genomics, transcriptomics, proteomics, laboratory investigations, wearable monitoring, liquid biopsy, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. Multidisciplinary expert feedback from participating institutions further strengthens algorithm performance through continuous clinical validation.

Federated collaborative intelligence ecosystems therefore establish international oncology networks capable of accelerating scientific discovery, improving equitable access to precision medicine, reducing institutional bias, and supporting global cancer research while maintaining responsible biomedical data stewardship.

14. Explainability, Validation, and Ethical Governance

Successful implementation of human–AI collaboration in oncology requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, confidence calibration, multimodal attention mapping, and counterfactual explanations identifying the imaging, molecular, pathological, physiological, and clinical variables responsible for predictive outputs.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, transparent reporting standards, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon informed consent, patient privacy, transparency, accountability, equitable access, fairness, responsible data governance, continuous post-deployment surveillance, and multidisciplinary oversight to ensure trustworthy integration of collaborative artificial intelligence into routine oncology practice.

15. Future Perspectives

Future human–AI collaborative ecosystems will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, single-cell sequencing, liquid biopsy, quantum computing, Internet of Medical Things (IoMT), robotics, cloud-native healthcare infrastructure, and autonomous clinical reasoning systems into unified precision oncology platforms.[26]

These next-generation computational ecosystems will continuously integrate molecular biology, radiological imaging, digital pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, pharmacological knowledge bases, and real-world clinical outcomes while autonomously generating evidence summaries, supporting multidisciplinary tumor boards, coordinating adaptive clinical trials, personalizing patient education, and continuously synthesizing biomedical knowledge.

Rather than replacing clinicians, future AI systems will increasingly function as trusted cognitive collaborators that augment clinical expertise while preserving human empathy, ethical judgment, contextual reasoning, and patient-centered communication.

16. Discussion

Human–artificial intelligence collaboration represents one of the most significant paradigm shifts in precision oncology by integrating foundation AI models, multimodal biomedical intelligence, digital biomarkers, digital twins, molecular biology, radiological imaging, digital pathology, laboratory biomarkers, wearable technologies, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike autonomous artificial intelligence systems, collaborative intelligence emphasizes partnership between clinicians and computational systems, combining algorithmic efficiency with human judgment, empathy, ethical reasoning, communication skills, and multidisciplinary expertise.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, precision immunotherapy, adaptive therapeutics, digital twins, remote patient monitoring, continuous learning, federated collaboration, digital health, survivorship management, multidisciplinary tumor boards, and intelligent clinical decision support demonstrate the extraordinary potential of collaborative intelligence to redefine future oncology. Nevertheless, successful implementation requires continued advances in

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1209

explainable artificial intelligence, multimodal data harmonization, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, clinician education, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, trustworthy human–AI collaboration is expected to become one of the foundational principles supporting intelligent precision oncology worldwide.

17. Conclusion

Human–artificial intelligence collaboration is transforming precision oncology by integrating foundation AI models with radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, digital biomarkers, digital twins, and longitudinal clinical intelligence into trustworthy computational ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive disease monitoring, and personalized cancer treatment throughout the patient journey.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, explainable artificial intelligence, and generative artificial intelligence are expected to further strengthen collaborative oncology ecosystems, enabling increasingly accurate molecular characterization, transparent clinical reasoning, adaptive therapeutics, continuous disease surveillance, and continuously personalized oncology care.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, nurses, healthcare organizations, policymakers, industry partners, patients, and regulatory agencies will accelerate the responsible implementation of trustworthy clinical intelligence systems. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, strengthen clinician confidence, reduce disparities in cancer care, accelerate translational research, and establish a new era of intelligent, transparent, collaborative, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.

3. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.

4. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881

5. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.

6. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

7. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7

8. Chakraborty, S. et al. (2022) ‘Multi-omics Integration in Oncology: From Data to Clinical Insights’, Cancer Cell, 40(8), pp. 805-823.

9. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL

CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

10. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7

11. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

12. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.

13. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8

14. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.

15. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.

16. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.

17. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.

18. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.

19. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.

20. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

21. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.

22. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.

23. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.

24. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.

25. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.

26. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.

27. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.

28. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

29. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.

30. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.